EP
SNNA

Elkfork Partners’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Elkfork Partners’s Portfolio SNNA Stock Details SNNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-6,048
Closed -$14K – 1055
2018
Q4 		$14K Sell
6,048
-17,668
-74% -$156K ﹤0.01% 998
2018
Q3 		$351K Buy
23,716
+1,148
+5% +$18.2K 0.01% 703
2018
Q2 		$343K Buy
22,568
+9,716
+76% +$165K 0.01% 636
2018
Q1 		$241K Buy
+12,852
New +$225K 0.01% 739

Other funds holding SNNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LM
Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Elkfork Partners's SNNA Position: Q1 2019 in Review

Elkfork Partners sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q1 2019, closing a stake of 6,048 shares — an estimated $14K sold.

Elkfork Partners first reported a position in SNNA in Q1 2018 and held it in 4 quarters. The position peaked at $351K in Q3 2018. 57 funds tracked by Wall St. Rank hold SNNA as of Q1 2019.

  • Elkfork Partners reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Elkfork Partners sold 6,048 Sienna Biopharmaceuticals, Inc. shares in Q1 2019, an estimated $14K.
  • Elkfork Partners first reported a position in Sienna Biopharmaceuticals, Inc. in Q1 2018 and held it in 4 quarters.
  • Elkfork Partners's Sienna Biopharmaceuticals, Inc. position peaked at $351K in Q3 2018.
  • 57 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q1 2019.

Based on Elkfork Partners's 13F filing for Q1 2019, filed 13 May 2019.